News

Consolidated Financial Results FY2022/3 Presentation Materials

Download
Consolidated Financial Results FY2022/3 Presentation
Consolidated Financial Resutls Presentat
Adobe Acrobat Document 2.1 MB
Read More

Corporate Governance Report

SNBL is pleased to announce that the English version of our Corporate Governance Report (Dec 2021) is now ready for stakeholders.

Read More

Sustainability Report 2021

SNBL is pleased to announce that the English version of our Sustainability Report 2021 is now ready for stakeholders.

Read More

Consolidated Financial Results H1 FY2021 Presentation

Download
Consolidated Financial Results H1 FY2021 Presentation Material
Consolidated Financial Resutls H1 FY2021
Adobe Acrobat Document 1.9 MB
Read More

Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022

Download
Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022
Financial Results 1H FY202203.pdf
Adobe Acrobat Document 937.5 KB

Revisions of the Earnings Forecasts for the Six Months and Full-Year of the FY Ending March 31, 2022

SNBL revised its earnings forecasts for the six months and full-year of the fiscal year ending March 31, 2022.

Read More

Notice Regarding Establishment of SDGs Committee

SNBL has established a Sustainable Developmental Goals (SDGs) committee.

Please see the link below for more details.

Read More

New brochures section

We have added a brochures section featuring overviews of our capabilities in antisense oligonucleotide therapeutics and gene therapy.
Please contact us at info@snbl.co.jp if you would like further information on our work in these areas at SNBL.

SNBL to participate in development of a prophylactic DNA vaccine for COVID-19

SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19. The role of SNBL is to plan and conduct the preclinical safety studies of the DNA vaccine, which has collaboratively been developed by AnGes, Inc. and Osaka University, in order to conduct the clinical trial as early as possible.   This vaccine uses plasmid DNA technology which means that it can be produced faster than attenuated vaccines. DNA vaccines are safe and work by inoculating a plasmid encoding the protein of the target pathogen.

 

SNBL's mission is to free patients from suffering, by supporting drug development and improving medical technology, and participation in this project gives SNBL the chance to do so for those suffering from the novel coronavirus.